Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.42 |
| ▸ | F10 | P00742 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31535977 | 0.88 | TRPV4 (0.56) | ALDH1A1SMN1; SMN2POLBTSHRHPGD | |
| SCHEMBL25045980 | 0.86 | TRPV4 (0.62) | ALDH1A1SMN1; SMN2POLBTSHRHPGD | |
| SCHEMBL30184710 | 0.86 | TRPV4 (0.62) | ALDH1A1SMN1; SMN2POLBTSHRHPGD | |
| SCHEMBL10638959 | 0.85 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2POLBTSHRHPGD | |
| SCHEMBL20057557 | 0.85 | TRPV4 (0.47) | ALDH1A1SMN1; SMN2POLBTSHRHPGD | |
| SCHEMBL10960621 | 0.84 | SMN1; SMN2 (0.61) | ALDH1A1SMN1; SMN2POLBTSHRHPGD | |
| SCHEMBL10880591 | 0.83 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2POLBTSHRHPGD | |
| SCHEMBL31411917 | 0.83 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2POLBTSHRHPGD | |
| SCHEMBL10642055 | 0.83 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2POLBTSHRHPGD | |
| SCHEMBL741127 | 0.82 | ALDH1A1 (0.59) | ALDH1A1SMN1; SMN2POLBTSHRHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026099404-A1 | SULFONYLUREA DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | QUBIT PHARMACEUTICALS (FR) | 2026-05-15 | — | — | WO | disclosed |
| EP-4741375-A1 | SULFONYLUREA DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | Qubit Pharmaceuticals (FR) | 2026-05-13 | — | — | EP | disclosed |
| US-20250122182-A1 | MYST Inhibitors | Isosterix, Inc. | 2025-04-17 | — | — | US | disclosed |
| EP-4335439-A2 | COMPOUNDS | CTXT PTY LTD (AU) | 2024-03-13 | — | — | EP | disclosed |
| EP-3810602-B1 | COMPOUNDS | CTXT PTY LTD (AU) | 2023-11-01 | — | — | EP | disclosed |
| EP-3810602-B1 | COMPOUNDS | CTXT PTY LTD (AU) | 2023-11-01 | — | — | EP | disclosed |
| US-11673867-B2 | Sulfonamide derivative or pharmaceutically acceptable acid-addition salt | UNIVERSITY OF TSUKUBA (JP) | 2023-06-13 | — | — | US | disclosed |
| US-11673867-B2 | Sulfonamide derivative or pharmaceutically acceptable acid-addition salt | UNIVERSITY OF TSUKUBA (JP) | 2023-06-13 | — | — | US | disclosed |
| US-11673867-B2 | Sulfonamide derivative or pharmaceutically acceptable acid-addition salt | UNIVERSITY OF TSUKUBA (JP) | 2023-06-13 | — | — | US | disclosed |
| EP-3725780-B1 | SULFONAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE ACID-ADDITION SALT | UNIV TSUKUBA (JP) | 2023-03-01 | — | — | EP | disclosed |
| WO-2019243491-A1 | COMPOUNDS | CTXT PTY LIMITED (AU) | 2019-12-26 | — | — | WO | disclosed |
| EP-2718264-B1 | BENZOCYCLOHEPTENE ACETIC ACIDS | HOFFMANN LA ROCHE (CH) | 2015-08-05 | — | — | EP | disclosed |
| EP-2718264-A1 | BENZOCYCLOHEPTENE ACETIC ACIDS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-04-16 | — | — | EP | disclosed |
| WO-2012168162-A1 | BENZOCYCLOHEPTENE ACETIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-12-13 | — | — | WO | disclosed |
| US-20120309796-A1 | BENZOCYCLOHEPTENE ACETIC ACIDS | FIROOZNIA FARIBORZ (US) | 2012-12-06 | — | — | US | disclosed |
| US-4766241-A | LOWER ACUTE TOXICITY | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-08-23 | — | — | US | disclosed |
| US-4607030-A | ANTIEDEMICS, HYPOTENSIVES | HOECHST AKTIENGESELLSCHAFT (DE) | 1986-08-19 | — | — | US | disclosed |
| EP-0088346-B1 | 2-AMINOMETHYL-PHENOL DERIVATIVES, PROCESS FOR THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | HOECHST AKTIENGESELLSCHAFT (DE) | 1985-06-05 | — | — | EP | disclosed |
| EP-0088345-A2 | 2-Aminomethyl-6-sulfamoylphenol derivatives, process for their preparation, their use and pharmaceutical preparations based on these compounds | HOECHST AKTIENGESELLSCHAFT (DE) | 1983-09-14 | — | — | EP | disclosed |
| EP-0088346-A2 | 2-Aminomethyl-phenol derivatives, process for their preparation, their use and pharmaceutical compositions containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1983-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11673867-B2 | Sulfonamide derivative or pharmaceutically acceptable acid-addition salt | HCRTR2, HCRTR1, NPSR1 | ALDH1A1 1094/4885SMN1; SMN2 985/4885POLB 4766/4885 |
| US-20250122182-A1 | MYST Inhibitors | MNAT1, SUGT1, ACAT2 | ALDH1A1 3906/4885SMN1; SMN2 3192/4885POLB 1364/4885 |
| US-20120309796-A1 | BENZOCYCLOHEPTENE ACETIC ACIDS | ACAT2, ACAT1, CYP27A1 | ALDH1A1 26/4885SMN1; SMN2 2829/4885POLB 2394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.